Associate Director, PC3I & Director, Program in Precision Oncology Innovation, PC3I
Charu Aggarwal, MD, MPH is an Associate Director and Innovation Faculty member at the Penn Center for Cancer Care Innovation (PC3I) as well as the Director of the Program in Precision Oncology Innovation at PC3I. She is the Leslye Heisler Associate Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania’s Perelman School of Medicine. She is an active member of the Abramson Cancer Center (ACC) where she serves as Physician Leader for the clinical research program for Airways Malignancies.
Dr. Aggarwal specializes in the management of patients with lung cancer, with a specific and clinical research focus on the development of novel immunotherapeutic approaches, and the discovery and application of biomarkers to guide therapy and monitor treatment. She serves as the local and national principal investigator for multiple clinical trials focusing on the development of “targeted” immunotherapeutic approaches including cellular therapy and CAR-T for solid tumors. Dr. Aggarwal has led trials evaluating the role of plasma-based next generation sequencing in the management of patients with metastatic lung cancer. Dr. Aggarwal performs patient-centered, scientifically relevant novel immunotherapy clinical trials that will make a tangible impact and advance our understanding of immunotherapy in patients with lung cancer.